Cargando…

Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells

BACKGROUND: Amplification of aurora kinase A (AK-A) overrides the mitotic spindle assembly checkpoint, inducing resistance to taxanes. RNA interference targeting AK-A in human pancreatic cancer cell lines enhanced taxane chemosensitivity. In this study, a novel AK-A inhibitor, CYC3, was investigated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Y, Richards, F M, Krippendorff, B-F, Bramhall, J L, Harrington, J A, Bapiro, T E, Robertson, A, Zheleva, D, Jodrell, D I
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493865/ https://www.ncbi.nlm.nih.gov/pubmed/23037716 http://dx.doi.org/10.1038/bjc.2012.450

Ejemplares similares

Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo
por: Bapiro, T E, et al.
Publicado: (2014)

Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase
por: Di Gennaro, E, et al.
Publicado: (2010)

Aurora B expression modulates paclitaxel response in non-small cell lung cancer
por: Al-Khafaji, Ahmed SK, et al.
Publicado: (2017)

A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC
por: Dean, E J, et al.
Publicado: (2010)

Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1
por: Xu, Li, et al.
Publicado: (2017)

Antiproliferative effects of sapacitabine (CYC682), a novel 2′-deoxycytidine-derivative, in human cancer cells
por: Serova, M, et al.
Publicado: (2007)

Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma
por: Tavanti, E, et al.
Publicado: (2013)

Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells
por: Tao, Y, et al.
Publicado: (2007)

NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel
por: Negishi, T, et al.
Publicado: (2006)

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)

Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer
por: Rajeshkumar, N V, et al.
Publicado: (2016)

A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer
por: Veltkamp, S A, et al.
Publicado: (2006)

miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer
por: Shen, Y, et al.
Publicado: (2013)

Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer
por: Azzariti, A, et al.
Publicado: (2011)

(212)Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint
por: Yong, K J, et al.
Publicado: (2013)

Role of the progesterone receptor for paclitaxel resistance in primary breast cancer
por: Schmidt, M, et al.
Publicado: (2007)

NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel
por: Hamaguchi, T, et al.
Publicado: (2005)

Expression of V(1A) and GRP receptors leads to cellular transformation and increased sensitivity to substance-P analogue-induced growth inhibition
por: MacKinnon, A C, et al.
Publicado: (2005)

Paclitaxel resistance in untransformed human mammary epithelial cells is associated with an aneuploidy-prone phenotype
por: Bouchet, B P, et al.
Publicado: (2007)

Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death
por: Obiorah, I, et al.
Publicado: (2014)

Acquisition of epithelial–mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells
por: Yang, Q, et al.
Publicado: (2014)

Stress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damage
por: Reeder, A, et al.
Publicado: (2015)

A leukotriene B(4) receptor-2 is associated with paclitaxel resistance in MCF-7/DOX breast cancer cells
por: Kim, H, et al.
Publicado: (2013)

Kinase-driven metabolic signalling as a predictor of response to carboplatin–paclitaxel adjuvant treatment in advanced ovarian cancers
por: Sereni, Maria Isabella, et al.
Publicado: (2017)

The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers
por: Goto, T, et al.
Publicado: (2008)

Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel
por: Martinelli, M, et al.
Publicado: (2007)

ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
por: Vaidyanathan, Aparajitha, et al.
Publicado: (2016)

In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival
por: Bicaku, E, et al.
Publicado: (2012)

α-Tocopheryl succinate and TRAIL selectively synergise in induction of apoptosis in human malignant mesothelioma cells
por: Tomasetti, M, et al.
Publicado: (2004)

Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer
por: Sun, S, et al.
Publicado: (2015)

Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging
por: Vassileva, V, et al.
Publicado: (2008)

Bone marrow-derived mesenchymal stromal cells promote colorectal cancer cell death under low-dose irradiation
por: Feng, Hao, et al.
Publicado: (2018)

Anti-Tumour Efficacy of Capecitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer
por: Courtin, Aurélie, et al.
Publicado: (2013)

Immunosuppressive effects of radiation on human dendritic cells: reduced IL-12 production on activation and impairment of naïve T-cell priming
por: Merrick, A, et al.
Publicado: (2005)

Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation
por: Hendrikx, J J M A, et al.
Publicado: (2014)

Early immunisation with dendritic cells after allogeneic bone marrow transplantation elicits graft vs tumour reactivity
por: Gigi, V, et al.
Publicado: (2013)

Interferon-β gene-modified human bone marrow mesenchymal stem cells attenuate hepatocellular carcinoma through inhibiting AKT/FOXO3a pathway
por: Xie, C, et al.
Publicado: (2013)

Modulating cancer cell survival by targeting intracellular cholesterol transport
por: Kuzu, Omer F, et al.
Publicado: (2017)

Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer
por: Mochiki, E, et al.
Publicado: (2012)

Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients
por: Lam, Siu W, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dc01q1m8l9rg6h59hic2kadmn9